Key clinical point: Adding veliparib to chemotherapy improves PFS in patients with BRCA-mutated breast cancer.
Major finding: Investigator-assessed median PFS: 14.5 vs. 12.6 months with veliparib vs. placebo (HR, 0.71).
Study details: The randomized, placebo-controlled phase 3 BROCADE 3 study of 509 patients.
Disclosures: AbbVie funded the study. Dr. Diéras reported advisory/consultancy roles for several pharmaceutical companies including AbbVie. Dr. Loi reported relationships with numerous pharmaceutical companies.
Diéras V et al. ESMO 2019, Abstract LBA9.